Market Overview:
The global cardiovascular disease drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cardiovascular diseases, rising geriatric population, and technological advancements in the field of cardiology. Based on type, the global cardiovascular disease drugs market is segmented into heparin, coumadin, sectral, zebeta, lopressor, toprol XL, norvasc and lotrel. The heparin segment is expected to dominate the global market during the forecast period owing to its high usage in surgeries and other medical procedures. Based on application type; asischemic heart disease accounted for majority share of revenue generated by this market in 2017 and it is projected that this trend will continue over the forecast period as well.
Product Definition:
Cardiovascular Disease Drugs are used to treat heart conditions and diseases. They work by improving blood flow and preventing the build-up of plaque in the arteries. This can help to reduce the risk of heart attack, stroke, and other cardiovascular problems.
Heparin:
Heparin is a type of blood thinner. It works by reducing the formation of blood clots. The drug has been used for decades and was first synthesized in 1965. Heparin is available as both synthetic and natural products, however, only natural heparin has been approved by the Food and Drug Administration (FDA) for use in humans to treat deep vein thrombosis or pulmonary embolism.
Coumadin:
Coumadin (warfarin) is a type of anticoagulant drug used to prevent blood clotting. It's most commonly prescribed for patients with atrial fibrillation, but it can be used in other cardiac conditions as well. Coumadin has several brand names such as warfarol, Mikocel, and Wafaric among others.
Application Insights:
Asischemic heart disease accounted for the largest share in 2015 owing to the increasing prevalence of asymptomatic patients suffering from atheromatous plaques. Asischemic heart diseases are also known as non-occlusive coronary artery diseases and affect approximately 50 million individuals in North America. The condition is characterized by a history of cigarette smoking, high blood pressure levels, and cholesterol levels above normal limits.
The application segment is further categorized into dyslipidemia, stroke, thrombosis/thrombo-embolism, stroke prevention through anticoagulants therapy (AT), atherosclerosis/coronary artery disease (CAD), peripheral artery disease (PAD), and others.
Regional Analysis:
North America dominated the global market in 2017 owing to favorable healthcare policies, high disposable income, and availability of advanced medical facilities. Moreover, increasing prevalence of CVDs is also expected to drive the regional market over the forecast period. In addition, growing awareness about risk factors such as smoking and alcohol consumption is further anticipated to fuel growth during the forecast period.
Asia Pacific region is projected to witness lucrative growth over the coming years due to rising geriatric population coupled with an increase in lifestyle-associated diseases such as diabetes and cardiac disorders which are majorly caused by stress & anxiety disorder or unhealthy dieting habits among others. Furthermore, economic development has led people towards a sedentary life style resulting into increased obesity levels which further leads toward cardiovascular diseases (CVDs). Such factors are expected result in significant demand for drugs within Asia Pacific region during 2018 - 2030 time frame thereby driving its overall revenue share at a significant rate throughout the study period.
Growth Factors:
- Increasing prevalence of cardiovascular diseases (CVDs) due to changing lifestyles and aging population.
- Growing demand for novel and expensive drugs to treat CVDs.
- Rising awareness about the benefits of early diagnosis and treatment of CVDs among patients and healthcare professionals.
- increasing incidence of obesity and diabetes, which are major risk factors for developing CVDs.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cardiovascular Disease Drugs Market Research Report
By Type
Heparin, Coumadin, Sectral, Zebeta, Lopressor, Toprol XL, Norvasc, Lotrel, Others
By Application
Asischemic Heart Disease, Dyslipidemia, Stroke, Thrombosis, Atherosclerosis, Coronary Artery Diseases, Peripheral Artery Disease, Others
By Companies
AstraZeneca, Johnson & Johnson, Pfizer, Sanofi, Merck, Daiichi Sankyo Company Limited, Novartis, Bayer, Takeda Pharmaceutical, Roche, AstraZeneca, Actelion Pharmaceuticals, Boehringer Ingelheim, Astellas Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
189
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Cardiovascular Disease Drugs Market Report Segments:
The global Cardiovascular Disease Drugs market is segmented on the basis of:
Types
Heparin, Coumadin, Sectral, Zebeta, Lopressor, Toprol XL, Norvasc, Lotrel, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Asischemic Heart Disease, Dyslipidemia, Stroke, Thrombosis, Atherosclerosis, Coronary Artery Diseases, Peripheral Artery Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Johnson & Johnson
- Pfizer
- Sanofi
- Merck
- Daiichi Sankyo Company Limited
- Novartis
- Bayer
- Takeda Pharmaceutical
- Roche
- AstraZeneca
- Actelion Pharmaceuticals
- Boehringer Ingelheim
- Astellas Pharma
Highlights of The Cardiovascular Disease Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Heparin
- Coumadin
- Sectral
- Zebeta
- Lopressor
- Toprol XL
- Norvasc
- Lotrel
- Others
- By Application:
- Asischemic Heart Disease
- Dyslipidemia
- Stroke
- Thrombosis
- Atherosclerosis
- Coronary Artery Diseases
- Peripheral Artery Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cardiovascular Disease Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cardiovascular disease drugs are medications used to treat heart conditions such as angina, a heart attack, or stroke.
Some of the major companies in the cardiovascular disease drugs market are AstraZeneca, Johnson & Johnson, Pfizer, Sanofi, Merck, Daiichi Sankyo Company Limited, Novartis, Bayer, Takeda Pharmaceutical, Roche, AstraZeneca, Actelion Pharmaceuticals, Boehringer Ingelheim, Astellas Pharma.
The cardiovascular disease drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cardiovascular Disease Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cardiovascular Disease Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cardiovascular Disease Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cardiovascular Disease Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cardiovascular Disease Drugs Market Size & Forecast, 2020-2028
4.5.1 Cardiovascular Disease Drugs Market Size and Y-o-Y Growth
4.5.2 Cardiovascular Disease Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Heparin
5.2.2 Coumadin
5.2.3 Sectral
5.2.4 Zebeta
5.2.5 Lopressor
5.2.6 Toprol XL
5.2.7 Norvasc
5.2.8 Lotrel
5.2.9 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Asischemic Heart Disease
6.2.2 Dyslipidemia
6.2.3 Stroke
6.2.4 Thrombosis
6.2.5 Atherosclerosis
6.2.6 Coronary Artery Diseases
6.2.7 Peripheral Artery Disease
6.2.8 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cardiovascular Disease Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cardiovascular Disease Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Heparin
9.6.2 Coumadin
9.6.3 Sectral
9.6.4 Zebeta
9.6.5 Lopressor
9.6.6 Toprol XL
9.6.7 Norvasc
9.6.8 Lotrel
9.6.9 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Asischemic Heart Disease
9.10.2 Dyslipidemia
9.10.3 Stroke
9.10.4 Thrombosis
9.10.5 Atherosclerosis
9.10.6 Coronary Artery Diseases
9.10.7 Peripheral Artery Disease
9.10.8 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Heparin
10.6.2 Coumadin
10.6.3 Sectral
10.6.4 Zebeta
10.6.5 Lopressor
10.6.6 Toprol XL
10.6.7 Norvasc
10.6.8 Lotrel
10.6.9 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Asischemic Heart Disease
10.10.2 Dyslipidemia
10.10.3 Stroke
10.10.4 Thrombosis
10.10.5 Atherosclerosis
10.10.6 Coronary Artery Diseases
10.10.7 Peripheral Artery Disease
10.10.8 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Heparin
11.6.2 Coumadin
11.6.3 Sectral
11.6.4 Zebeta
11.6.5 Lopressor
11.6.6 Toprol XL
11.6.7 Norvasc
11.6.8 Lotrel
11.6.9 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Asischemic Heart Disease
11.10.2 Dyslipidemia
11.10.3 Stroke
11.10.4 Thrombosis
11.10.5 Atherosclerosis
11.10.6 Coronary Artery Diseases
11.10.7 Peripheral Artery Disease
11.10.8 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Heparin
12.6.2 Coumadin
12.6.3 Sectral
12.6.4 Zebeta
12.6.5 Lopressor
12.6.6 Toprol XL
12.6.7 Norvasc
12.6.8 Lotrel
12.6.9 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Asischemic Heart Disease
12.10.2 Dyslipidemia
12.10.3 Stroke
12.10.4 Thrombosis
12.10.5 Atherosclerosis
12.10.6 Coronary Artery Diseases
12.10.7 Peripheral Artery Disease
12.10.8 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Heparin
13.6.2 Coumadin
13.6.3 Sectral
13.6.4 Zebeta
13.6.5 Lopressor
13.6.6 Toprol XL
13.6.7 Norvasc
13.6.8 Lotrel
13.6.9 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Asischemic Heart Disease
13.10.2 Dyslipidemia
13.10.3 Stroke
13.10.4 Thrombosis
13.10.5 Atherosclerosis
13.10.6 Coronary Artery Diseases
13.10.7 Peripheral Artery Disease
13.10.8 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cardiovascular Disease Drugs Market: Competitive Dashboard
14.2 Global Cardiovascular Disease Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Johnson & Johnson
14.3.3 Pfizer
14.3.4 Sanofi
14.3.5 Merck
14.3.6 Daiichi Sankyo Company Limited
14.3.7 Novartis
14.3.8 Bayer
14.3.9 Takeda Pharmaceutical
14.3.10 Roche
14.3.11 AstraZeneca
14.3.12 Actelion Pharmaceuticals
14.3.13 Boehringer Ingelheim
14.3.14 Astellas Pharma
